Morgan Stanley Innate Pharma Sa Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Innate Pharma Sa stock. As of the latest transaction made, Morgan Stanley holds 43,524 shares of IPHA stock, worth $77,037. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,524
Previous 43,524
-0.0%
Holding current value
$77,037
Previous $84,000
17.86%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding IPHA
# of Institutions
9Shares Held
238KCall Options Held
0Put Options Held
0-
Optiver Holding B.V. Amsterdam, P786.8KShares$153,6140.01% of portfolio
-
Exchange Traded Concepts, LLC77.4KShares$136,9090.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il21.3KShares$37,6420.0% of portfolio
-
Ubs Group Ag8.41KShares$14,8820.0% of portfolio
-
Barclays PLC London, X0307Shares$5430.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $141M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...